AZ ups emerging markets bet with $200M plant in China

AstraZeneca ($AZN) has announced a $200 million investment to build a pharma manufacturing plant in China Medical City, Jiangsu Province. The company says the financial commitment is its largest ever in a single manufacturing facility.

The plant is expected to produce both intravenous and oral solid medicines.

The new plant "will complement our efforts to meet the medical needs of Chinese patients with medicines that are locally produced," AZ China president Mark Mallon says in the statement.

The new plant, for which AZ expects construction to be complete by late 2013, will also complement an existing manufacturing and supply site in Wuxi New District, Jiangsu Province.

- see the AZ release
- here's the story

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

Branded drug sales in China could suffer in the short term as marketing activities for new meds are limited to reduce the risk of contagion.